HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 269 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,709,982 | -79.8% | 228,010 | -80.9% | 0.00% | -77.8% |
| Q2 2023 | $43,147,619 | +17.2% | 1,196,219 | +24.1% | 0.01% | +12.5% |
| Q1 2023 | $36,823,600 | +104.4% | 964,221 | +204.5% | 0.01% | +100.0% |
| Q4 2022 | $18,018,751 | +521.3% | 316,674 | +331.7% | 0.00% | – |
| Q3 2022 | $2,900,000 | -89.4% | 73,348 | -88.2% | 0.00% | -100.0% |
| Q2 2022 | $27,361,000 | +723.9% | 621,846 | +646.8% | 0.01% | – |
| Q1 2022 | $3,321,000 | -64.9% | 83,268 | -64.6% | 0.00% | -100.0% |
| Q4 2021 | $9,449,000 | +43.1% | 234,970 | +44.8% | 0.00% | 0.0% |
| Q3 2021 | $6,601,000 | -19.0% | 162,249 | -9.6% | 0.00% | 0.0% |
| Q2 2021 | $8,152,000 | -17.0% | 179,501 | -23.8% | 0.00% | 0.0% |
| Q1 2021 | $9,818,000 | -10.4% | 235,486 | -8.2% | 0.00% | -33.3% |
| Q4 2020 | $10,953,000 | +43.5% | 256,427 | -11.7% | 0.00% | +50.0% |
| Q3 2020 | $7,632,000 | -29.8% | 290,400 | -28.4% | 0.00% | -50.0% |
| Q2 2020 | $10,871,000 | +35.4% | 405,516 | -9.2% | 0.00% | +33.3% |
| Q1 2020 | $8,030,000 | +4.0% | 446,388 | +2.5% | 0.00% | 0.0% |
| Q4 2019 | $7,724,000 | +31.8% | 435,677 | +15.3% | 0.00% | +50.0% |
| Q3 2019 | $5,862,000 | -66.0% | 377,938 | -62.3% | 0.00% | -71.4% |
| Q2 2019 | $17,224,000 | +56.6% | 1,002,592 | +46.7% | 0.01% | +40.0% |
| Q1 2019 | $11,001,000 | +48.6% | 683,293 | +35.0% | 0.01% | +25.0% |
| Q4 2018 | $7,404,000 | +12.3% | 506,023 | +39.5% | 0.00% | +100.0% |
| Q3 2018 | $6,592,000 | +82.1% | 362,822 | +69.2% | 0.00% | +100.0% |
| Q2 2018 | $3,619,000 | +44.4% | 214,445 | +67.6% | 0.00% | -50.0% |
| Q1 2018 | $2,507,000 | -58.1% | 127,949 | -56.7% | 0.00% | -33.3% |
| Q4 2017 | $5,982,000 | +201.2% | 295,263 | +158.3% | 0.00% | +200.0% |
| Q3 2017 | $1,986,000 | -49.1% | 114,321 | -62.5% | 0.00% | -75.0% |
| Q2 2017 | $3,905,000 | +202.5% | 304,578 | +205.7% | 0.00% | – |
| Q1 2017 | $1,291,000 | -59.7% | 99,626 | -69.3% | 0.00% | -100.0% |
| Q4 2016 | $3,205,000 | +165.8% | 324,352 | +225.0% | 0.00% | +300.0% |
| Q3 2016 | $1,206,000 | +206.1% | 99,792 | +118.8% | 0.00% | – |
| Q2 2016 | $394,000 | -74.6% | 45,605 | -49.1% | 0.00% | -100.0% |
| Q4 2015 | $1,553,000 | -58.6% | 89,623 | -67.9% | 0.00% | -50.0% |
| Q3 2015 | $3,753,000 | +386.8% | 279,493 | +718.2% | 0.00% | +300.0% |
| Q2 2015 | $771,000 | -80.5% | 34,161 | -87.7% | 0.00% | -75.0% |
| Q1 2015 | $3,955,000 | +1819.9% | 276,935 | +1198.3% | 0.00% | – |
| Q4 2014 | $206,000 | -88.2% | 21,330 | -88.9% | 0.00% | -100.0% |
| Q3 2014 | $1,747,000 | -10.4% | 192,038 | -2.6% | 0.00% | 0.0% |
| Q2 2014 | $1,949,000 | +70.8% | 197,198 | +119.3% | 0.00% | +100.0% |
| Q1 2014 | $1,141,000 | -42.1% | 89,905 | -31.7% | 0.00% | -66.7% |
| Q4 2013 | $1,972,000 | +424.5% | 131,564 | +286.2% | 0.00% | +200.0% |
| Q3 2013 | $376,000 | -89.7% | 34,067 | -92.6% | 0.00% | -83.3% |
| Q2 2013 | $3,665,000 | – | 461,654 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |